



Source details

Current Clinical Microbiology Reports

Scopus coverage years: from 2014 to Present

Publisher: Springer Nature

E-ISSN: 2196-5471

Subject area: Medicine: Infectious Diseases Medicine: Microbiology (medical)

Source type: Journal

[View all documents >](#) [Set document alert](#) [Save to source list](#) [Source Homepage](#)

CiteScore 2021

6.3



SJR 2021

0.839



SNIP 2021

1.087



[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology



CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ▼

$$6.3 = \frac{527 \text{ Citations 2018 - 2021}}{84 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$7.2 = \frac{489 \text{ Citations to date}}{68 \text{ Documents to date}}$$

Last updated on 05 April, 2023 • Updated monthly

CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Medicine		
↳ Infectious Diseases	#78/295	73rd
Medicine		
↳ Microbiology (medical)	#34/118	71st

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.





Current Clinical Microbiology Reports

<p>COUNTRY</p> <p>Switzerland</p> <p> Universities and research institutions in Switzerland</p> <p> Media Ranking in Switzerland</p>	<p>SUBJECT AREA AND CATEGORY</p> <p>Medicine</p> <ul style="list-style-type: none"> Infectious Diseases Microbiology (medical) 	<p>PUBLISHER</p> <p>Springer International Publishing AG</p>	<p>H-INDEX</p> <p>22</p>
<p>PUBLICATION TYPE</p> <p>Journals</p>	<p>ISSN</p> <p>21965471</p>	<p>COVERAGE</p> <p>2014-2021</p>	<p>INFORMATION</p> <p>Homepage</p> <p>How to publish in this journal</p>

SCOPE









Current Clinical Microbiology Reports commissions expert reviews from leading scientists at the forefront of research in microbiology. The journal covers this broad field by dividing it into four key main areas of study: virology, bacteriology, parasitology, and mycology. Within each of the four sections, experts from around the world address important aspects of clinical microbiology such as immunology, diagnostics, therapeutics, antibiotics and antibiotic resistance, and vaccines. Some of the world's foremost authorities in the field of microbiology serve as section editors and editorial board members. Section editors select topics for which leading researchers are invited to contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, which are highlighted in annotated reference lists. These timely reviews of the literature examine the latest scientific discoveries and controversies as they emerge and are indispensable to both researchers and clinicians. The editorial board, composed of more than 20 internationally diverse members, reviews the annual table of contents, ensures that topics address all aspects of emerging research, and where applicable suggests topics of critical importance to various countries/regions.

Join the conversation about this journal

FIND SIMILAR JOURNALS

options

<p>1 PLoS Pathogens</p> <p>USA</p> <p>83% similarity</p>	<p>2 Viruses</p> <p>CHE</p> <p>80% similarity</p>	<p>3 Medical Microbiology and Immunology</p> <p>DEU</p> <p>79% similarity</p>	<p>4 Future Virology</p> <p>GBR</p> <p>79% similarity</p>	<p>5 Current Opinion in Virology</p> <p>NLD</p> <p>79% similarity</p>
--	---	---	---	---



Current Clinical Microbiology Reports

← Show this widget in your own website

Q2 Infectious Diseases
best quartile

SJR 2021
0.84

powered by scimagojr.com

Just copy the code below and paste within your html code:

``

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.



Rizwana 2 years ago

I want to publish an article regarding gut microbiota, what is the published cost in this journal.

← reply



Melanie Ortiz 2 years ago

SCImago Team

Dear Rizwana, thank you very much for your comment, we suggest you look for the author's instructions/submission guidelines in the journal's website. Best Regards, SCImago Team

Leave a comment

Name

Email

(will not be published)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS
Horatio (Satire 1, 1, 105)

[Cookie settings](#)

[Cookie policy](#)

CURRENT
CLINICAL
MICROBIOLOGY
REPORTS

EDITED BY
Dr. Yulia Yanovsky

**Microbial Anti-Cancer Therapy
and Prevention**

Section Editor • Yulia Yanovsky

Springer



Current Clinical Microbiology Reports

[Current Clinical Microbiology Reports](#) > [Editors](#)

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)

Editors

Editor-in-Chief:

Yohei Yamauchi, MD, PhD

Professor of Molecular Medicine
Institute of Pharmaceutical Sciences
Department of Chemistry and Applied Biosciences
ETH Zürich, Zürich, Switzerland

Sections and Section Editors:

Antimicrobial

Daniel Morse, PhD

Lecturer in Microbiology & Research Associate
School of Cellular and Molecular Medicine
University of Bristol
Bristol, UK

COVID-19, Immune Evasion and Therapies

Sho Iketani, PhD

Department of Microbiology and Immunology
Columbia University Irving Medical Center
New York, USA

Fungal Pathogenesis

Stephanie Diezmann, PhD

Senior Lecturer
School of Cellular and Molecular Medicine

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)

Mohali, India

Mycology

Bridget Barker, PhD

Associate Professor

Department of Biological Sciences

Northern Arizona University

Flagstaff, AZ, USA

Parasitology

Shokoofeh Shamsi, MSc, PhD, GCULT, GCULM

Professor in Veterinary Parasitology

School of Veterinary Sciences

Charles Sturt University

Bathurst, Australia

Pediatric Viral Infections

Tetsushi Yoshikawa, MD, PhD

Professor

Department of Pediatrics

Fujita Health University School of Medicine

Toyoake, Aichi, Japan

Viral Latency

Meaghan Hancock, PhD

Assistant Professor

Vaccine and Gene Therapy Institute

Oregon Health & Science University

Portland, Oregon, USA

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)

Editorial Board:

Dov L. Boros, Ph.D.

Professor Emeritus
School of Medicine, Immunology and Microbiology
Wayne State University School of Medicine
Detroit, MI, USA

Stephanie Diezmann, PhD

Senior Lecturer
School of Cellular and Molecular Medicine
Infection and Immunity
University of Bristol
Bristol, UK

Jeffery A. Hobden, PhD

Associate Professor of Microbiology, Immunology & Parasitology
Department of Microbiology, Immunology and Parasitology
Louisiana State University Health
New Orleans, LA, USA

Eric Lafontaine, PhD

Professor
Dept. Infectious Diseases, College of Veterinary Medicine
University of Georgia
Athens, GA, USA

Andreas Pospischil, Ph.D

Professor
Institute of Veterinary Pathology
University of Zurich, Zurich, Switzerland

Robert Swanborg, Ph.D

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)

Queensland, Australia

Raghavendar R. Thipparthi, Ph.D

Associate Professor in the Department of Immunology and Microbiology
School of Medicine, Immunology and Microbiology
Wayne State University School of Medicine
Detroit, MI, USA

Jeffrey H. Withey, Ph.D

Associate Professor in the Department of Immunology and Microbiology
School of Medicine, Immunology and Microbiology
Wayne State University School of Medicine
Detroit, MI, USA

Oren Kobiler, M.D. Ph.D

Senior lecturer
Department of Clinical Microbiology and Immunology
Sackler School of Medicine
Tel Aviv University
Tel Aviv, Israel

For authors

[Submission guidelines](#)

[Manuscript editing services](#)

[Ethics & disclosures](#)

[Open Access fees and funding](#)

[Contact the journal](#)

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

Provide Feedback

No Thanks

Explore

[Online first articles](#)

[Volumes and issues](#)

[Collections](#)

[Sign up for alerts](#)



Publish with us

[Authors & Editors](#)

[Journal authors](#)

[Publishing ethics](#)

[Open Access & Springer](#)

Discover content

[SpringerLink](#)

[Books A-Z](#)

[Journals A-Z](#)

[Video](#)

Other services

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)

[About us](#)

[Help & Support](#)

[Contact us](#)

[Press releases](#)

[Impressum](#)

Legal

[General term & conditions](#)

[California Privacy Statement](#)

[Rights & permissions](#)

[Privacy](#)

[How we use cookies](#)

[Manage cookies/Do not sell my data](#)

[Accessibility](#)

Not logged in - 36.68.218.108

Not affiliated

SPRINGER NATURE

© 2023 Springer Nature Switzerland AG. Part of [Springer Nature](#).

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)



Current Clinical Microbiology Reports

[Current Clinical Microbiology Reports](#) > [Editors](#)

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)

Editors

Editor-in-Chief:

Yohei Yamauchi, MD, PhD

Professor of Molecular Medicine
Institute of Pharmaceutical Sciences
Department of Chemistry and Applied Biosciences
ETH Zürich, Zürich, Switzerland

Sections and Section Editors:

Antimicrobial

Daniel Morse, PhD

Lecturer in Microbiology & Research Associate
School of Cellular and Molecular Medicine
University of Bristol
Bristol, UK

COVID-19, Immune Evasion and Therapies

Sho Iketani, PhD

Department of Microbiology and Immunology
Columbia University Irving Medical Center
New York, USA

Fungal Pathogenesis

Stephanie Diezmann, PhD

Senior Lecturer
School of Cellular and Molecular Medicine

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)

Mohali, India

Mycology

Bridget Barker, PhD

Associate Professor

Department of Biological Sciences

Northern Arizona University

Flagstaff, AZ, USA

Parasitology

Shokoofeh Shamsi, MSc, PhD, GCULT, GCULM

Professor in Veterinary Parasitology

School of Veterinary Sciences

Charles Sturt University

Bathurst, Australia

Pediatric Viral Infections

Tetsushi Yoshikawa, MD, PhD

Professor

Department of Pediatrics

Fujita Health University School of Medicine

Toyoake, Aichi, Japan

Viral Latency

Meaghan Hancock, PhD

Assistant Professor

Vaccine and Gene Therapy Institute

Oregon Health & Science University

Portland, Oregon, USA

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)

Editorial Board:

Dov L. Boros, Ph.D.

Professor Emeritus
School of Medicine, Immunology and Microbiology
Wayne State University School of Medicine
Detroit, MI, USA

Stephanie Diezmann, PhD

Senior Lecturer
School of Cellular and Molecular Medicine
Infection and Immunity
University of Bristol
Bristol, UK

Jeffery A. Hobden, PhD

Associate Professor of Microbiology, Immunology & Parasitology
Department of Microbiology, Immunology and Parasitology
Louisiana State University Health
New Orleans, LA, USA

Eric Lafontaine, PhD

Professor
Dept. Infectious Diseases, College of Veterinary Medicine
University of Georgia
Athens, GA, USA

Andreas Pospischil, Ph.D

Professor
Institute of Veterinary Pathology
University of Zurich, Zurich, Switzerland

Robert Swanborg, Ph.D

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)

Queensland, Australia

Raghavendar R. Thipparthi, Ph.D

Associate Professor in the Department of Immunology and Microbiology
School of Medicine, Immunology and Microbiology
Wayne State University School of Medicine
Detroit, MI, USA

Jeffrey H. Withey, Ph.D

Associate Professor in the Department of Immunology and Microbiology
School of Medicine, Immunology and Microbiology
Wayne State University School of Medicine
Detroit, MI, USA

Oren Kobiler, M.D. Ph.D

Senior lecturer
Department of Clinical Microbiology and Immunology
Sackler School of Medicine
Tel Aviv University
Tel Aviv, Israel

For authors

[Submission guidelines](#)

[Manuscript editing services](#)

[Ethics & disclosures](#)

[Open Access fees and funding](#)

[Contact the journal](#)

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

Provide Feedback

No Thanks

Explore

[Online first articles](#)

[Volumes and issues](#)

[Collections](#)

[Sign up for alerts](#)



Publish with us

[Authors & Editors](#)

[Journal authors](#)

[Publishing ethics](#)

[Open Access & Springer](#)

Discover content

[SpringerLink](#)

[Books A-Z](#)

[Journals A-Z](#)

[Video](#)

Other services

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)

[About us](#)

[Help & Support](#)

[Contact us](#)

[Press releases](#)

[Impressum](#)

Legal

[General term & conditions](#)

[California Privacy Statement](#)

[Rights & permissions](#)

[Privacy](#)

[How we use cookies](#)

[Manage cookies/Do not sell my data](#)

[Accessibility](#)

Not logged in - 36.68.218.108

Not affiliated

SPRINGER NATURE

© 2023 Springer Nature Switzerland AG. Part of [Springer Nature](#).

SPRINGER NATURE

Do you publish research?

If so, would you be willing to take 2 minutes to answer a few questions about your experience of publishing in the last year or so?

[Provide Feedback](#)

[No Thanks](#)



Prostate Cancer Microbiome: A Narrative Review of What We Know So Far

Yudhistira Pradnyan Kloping^{1,2} · Lukman Hakim^{1,3}

Accepted: 24 March 2022 / Published online: 8 April 2022
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Abstract

Purpose of review The role of the microbiome in mediating the pathogenesis of prostate cancer has been suggested to have a role in the carcinogenesis process. This review aimed to explore the potential role of the prostate, urinary, and gut microbiomes in prostate cancer development.

Recent Findings Current literature indicates that the discovery of microbes, potentially associated with prostate cancer, raises more questions about whether their presence was merely coincidental or due to contamination. Studies have discovered bacteria and viruses in the prostate, urinary tract, and gastrointestinal tract. However, whether there is a prostate microbiome is still unclear due to the study design limitations and small sample size.

Summary Even though the link between the specific microbiome and prostate cancer has not been established, findings suggest that chronic inflammation and immune system modulation associated with the microbiome are the underlying mechanisms increasing the risk of prostate cancer development.

Keywords Prostate cancer · Microbiome · Prostate microbiome · Genitourinary microbiome · Gut microbiome · Cancer

Introduction

The human body contains more than 38 trillion microbes, coexisting with our cells [1]. Microbes consisting of bacteria, viruses, archaeobacteria, protista, and fungi mostly live in the aerodigestive tract and other areas of the body, including the urinary tract [2]. The definition of ‘microbiota’ refers to a collection of microorganisms, consisting of bacteria; eukaryotes; and viruses, existing in an environment, which are found in all multicellular organisms [3]. The term ‘microbiome’ refers to the interaction of a particular microbe

with a disease, obtained from processing microbial DNA [4]. Several studies even suggest that the microbiome is heritable as a polygenic trait [5]. These microbes play a major role in many health and disease processes, in which they are believed to maintain a symbiotic relationship with the human body in metabolism, immune response, and reproduction [6, 7]. Research in the human microbiome as a part of ecological research has been conducted for decades; however, the role of the microbiome in certain diseases has only been studied in recent years [8]. Diseases such as obesity, psoriasis, inflammatory bowel disease (IBS), and colorectal carcinoma have been linked to the microbiome [9, 10, 11, 12]. Cancer is a multifactorial disease, involving genetic, immune, environmental, and psychological factors causing its management to be difficult [13, 14]. Knowledge regarding factors influencing cancer development and progression has increased dramatically in the past two decades [15]. A specific approach for each type of malignancy has produced many studies evaluating tumor genome, epigenome, and microenvironment [16, 17]. Approximately 20% of a malignancy’s etiopathogenesis is related to the role of a microorganism, including the manipulation of a microbe on the stimulation or suppression of cancer cells [18]. Many studies

This article is part of the Topical Collection on *Microbial Anti-cancer Therapy and Prevention*

✉ Lukman Hakim
lukman-h@fk.unair.ac.id

¹ Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia

² Dr. Soetomo General-Academic Hospital, Surabaya, East Java, Indonesia

³ Universitas Airlangga Teaching Hospital, Surabaya, East Java, Indonesia

have explored how microbiota works in mediating the pathogenesis of several solid tumors based on the thorough investigations in several studies, including its potential for diagnosis and risk stratification [19, 20, 21]. Prostate cancer is the second most commonly found malignancy in men. Based on the data published by the GLOBOCAN database, it is the second most commonly found cancer and the fifth leading cause of cancer-related death among men in 2020, as shown in Figure 1 [22•]. The organ is responsible for producing fluid to give nutrition and facilitate sperm transport during ejaculation [23]. In recent years, studies investigating the role of inflammation and prostate carcinogenesis have been published, reporting many chronic inflammatory cells found in the histopathological examination of the prostate cancer tissue, especially in the peripheral zone [24, 25]. Proliferative inflammatory atrophy (PIA) are inflammatory lesions that exist in many glandular tissues with basal and secretory cells. These lesions are abundant in the peripheral zone of the prostate, thus the lesions are believed to be a precursor to prostate cancer cells [24].

Bacteria have been thought to cause chronic, low-grade inflammation which could induce neoplasia [4]. The interaction of some microbes with the prostate can be explained both directly and indirectly. Direct interaction involves the microbiome in the urinary tract and prostatic tissue, whereas indirect interaction involves the gut microbiome, including oral and fecal microbiomes [26, 27]. Microbiomes have been suggested to have a role in the entire carcinogenesis process from initiation to progression, thus affecting the consequences of a particular treatment [28]. Some bacteria are able to produce toxins that could increase the risk of

malignancy, such as colorectal cancer, gastric cancer, and bile cancers, such as *Salmonella typhi*, *Escherichia coli*, and *H. pylori* [29, 30]. Prostate cancer is the second-highest leading cause of cancer-specific mortality in the world, thus a thorough understanding regarding the risk and diagnosis for prevention, as well as management strategy for prostate cancer is necessary [31, 32]. Theoretically, natural microbiotic changes can increase the risk of prostate cancer development [33]. Chronic infection, the involvement of a genetic structure of a virus, and metabolic production can influence the prostatic carcinogenesis [34].

Prostate cancer management has advanced rapidly in the use of chemotherapy, androgen deprivation therapy, surgery, radiotherapy, and immunotherapy in recent years [35]. In the era of specific management strategies for each malignancy, a deep understanding of the specific microbiome for prostate cancer will be beneficial to increase the quality of management of prostate cancer patients [36]. With the introduction of novel therapies such as immunotherapy and the field of metagenomics and next-generation sequencing, the microbiome is expected to be the foundation of future therapeutic strategies for prostate cancer management [37].

Prostate Microbiome in Prostate Cancer Patients

There are only a few studies evaluating the prostate tissues of both healthy people and prostate cancer patients, in contrast with the abundant studies evaluating the microbiome of various parts of the body [38••, 39••]. Even though some




Figure 1 The cumulative risk of prostate cancer (a) incidence and (b) death in men aged up to 74 years old in 2020

studies have reported the presence of microbiome in prostate cancer tissue, whether there is a prostate microbiome is still unclear [28].

Bacteria Microbiome

One of the earliest prostate microbiome studies conducted in the year 2000 evaluated the specimens of prostate tissue taken from healthy, benign prostatic hyperplasia, and prostate cancer patients. They discovered bacteria in the radical and simple prostatectomy specimens performed on prostate cancer and BPH patients respectively, but not in the prostate tissue of healthy subjects [40••]. Folate and arginine metabolism pathways are associated with the presence of *Bacteroidetes* and *Streptococcal* species, which are enriched among prostate cancer patients [4]. Golombos et al. discovered an enrichment in *Bacteroidetes* in the stool of 12 prostate cancer patients and *Eubacterium* and *Faecalibacterium* in eight BPH patients. They reported enrichment of metabolically active pathways in patients with BPH compared to patients with cancer [38••]. Cavaretta et al. discovered that *Cutibacterium acnes* was present in the tumor, peri-tumor, and non-tumor tissue of prostate cancer patients undergoing radical prostatectomy [41••]. Several studies have linked the development of prostate cancer with the bacteria in an animal model [42]. However, the results of the study could be biased due to the possible specimen contamination, as *Cutibacterium acnes* is a common contaminant [43••]. There was a higher proportion of *Streptococcaceae* in non-tumor tissue compared to peri-tumor tissue. A higher proportion of *Staphylococcaceae* bacteria was found in tumor and peri-tumor tissue [41••]. The presence of *Streptococcaceae* in normal tissue may indicate the normal microbiome of a healthy prostate tissue as the bacteria are speculated to help maintain an ecosystem for the host environment [44]. However, the results may also be biased as both bacteria are frequent contaminants [45]. In another study, Feng et al. identified over 40 bacteria, with *Eschericia*, *Acinetobacter*, *Pseudomonas*, and *Propionibacterium* being the most prominent, taken from the frozen radical prostate specimens of 65 Chinese patients [46••]. Banerjee et al. managed to isolate mostly gram-negative bacteria from the formalin-fixed tissue of 50 prostate cancer patients [47••]. One of the major findings is the presence of *Helicobacter pylori* in more than 90% of prostate cancer tissue. They suggest that *Helicobacter pylori* might play a role in prostatic cancer development [47••]. However, other studies also find the bacteria in BPH specimens and non-tumor tissues [48•]. The studies evaluating the presence of microbes in tumor and non-tumor tissue from formalin-fixed tissue reported similar microbiota characteristics between both tissues [41••, 46••]. The results of these studies could not be concluded as to whether the

bacteria's presence is merely due to contamination could not be ruled out [49]. One of the most commonly associated bacteria with bacteria is *Mycoplasma genitalium*, as it can induce oncogenic transformation in both in vitro and in vivo studies [50]. In a study evaluating prostate cancer and BPH patients for various sexually transmitted infection (STI) bacteria, *Mycoplasma genitalium* was discovered to be independently associated with prostate cancer [51]. *Chlamydia trachomatis* has also been suggested to be a potential cause of prostate cancer [13]. A screening trial also suggested that the odds of developing prostate cancer are higher if a person is infected with sexually-transmitted bacteria [52]. Another study by Yu et al. investigated the presence of microbes in the seminal and prostatic fluids in men with BPH and prostate cancer due to the less invasive method of studying the prostate microbiome [53••]. Prostate cancer specimens had a significantly higher presence of *Alphaproteobacteria*, *Firmicutes*, *Bacteroidetes*, *Ochrobactrum*, *Propionimonas*, *Sphingomonas*, and *Lachnospiraceae* bacteria, but a much lower presence of *Eubacterium* and *Defluviicoccus* bacteria compared to BPH tissue specimens [53••]. The variety of bacteria found in many studies increases more questions whether there are many bacteria with the role of inducing prostate cancer progression or there isn't any bacterial microbiome responsible for prostate cancer carcinogenesis and their presence was merely coincidental or due to contamination.

Viral Microbiome

Viral etiologies have been proposed for prostate cancer for years [54, 55]. A study managed to isolate viruses from 80% of the evaluated prostate tissue, in which 40% were tumorigenic viruses including Human Papilloma Virus (HPV) with high-risk strains (16 and 18) and cytomegalovirus (CMV) [47••]. Viruses can prevent clearance from the host through immune tolerance by downregulating the stimulator of the interferon genes (STING) pathway [56]. Viral infections due to polyomavirus, HPV, and CMV have been found to be able to infect the prostate and have a higher prevalence in people with prostate cancer [34]. Some viruses can shut down the STING pathway from destroying the affected cells, including tumor cells, allowing further progression and proliferation to take place [57].

Urinary Microbiome in Prostate Cancer Patients

The role of a urinary tract is to excrete metabolism byproducts from the body's systemic circulation [58]. It is commonly believed that the urinary tract is sterile; however, several

studies have reported the presence of microbiome within the tract [59]. Even though both the gastrointestinal and urinary tracts' epithelial layers are exposed to bacteria, the density and type of microbes in both layers are vastly different [60]. The urinary tract is made specifically to filter, collect, and excrete the byproducts of metabolism without any leakage. Both kidneys receive 20% of the blood pumped by the cardiac with a 125 ml/minute filtration rate [61]. The gut microbes are the main source of metabolites. The metabolites will travel into the hepatic circulation and filtrated by the urinary tract [62]. This mechanism explains why bacteria residing in an area of the body could affect the bacteria in another location. The proximity between the urinary tract and prostate makes it easier for inflammatory pathogens to enter the prostatic duct via urinary reflux and cause infection [63]. Chronic inflammation occurring in the prostate or urinary tract could help provide a microenvironment that stimulates prostate carcinogenesis [64]. Some studies suggested that prostate cancer is with chronic prostatitis and chronic pelvic pain syndrome [65, 66]. Many basic science and clinical studies have attempted to investigate the microbiome of the prostate and urinary tract to determine its role in cancer development. The progress in contamination control techniques has allowed the identification of a natural tissue microbiome [67]. Currently, studies performed a 16S rRNA gene PCR on specimens to identify the presence of bacteria [68]. Theoretically, the occurrence of dysbiosis in the local tissue could lead to a chronic damage, slowly progressing into cancer development [69]. Several studies have investigated the presence of several bacteria and viruses residing in prostate cancer patients' urinary tract, which are not found in healthy patients [65]. The urinary microbiome of 135 prostate cancer patients undergoing a prostate biopsy was evaluated by Shrestha et al. with interesting results. In both positive and negative biopsy results, *Staphylococcus*, *Streptococcus*, and *Corynebacterium* species were found in similar numbers. Other species, such as *Anaerococcus lactolyticus*, *Anaerococcus obesiensis*, *Actinobaculum schaalii*, *Varibaculum cambriense*, and *Propionimicrobium lymphophilum* were found to be higher in patients with a positive biopsy result [39••]. Another study discovered the presence of *Bacteroides*, *Streptococcus*, and *Veillonella* in the urine sample following a prostatic massage in prostate cancer patients. These bacteria were found to be higher compared to the results of BPH patients. However, it should be noted that the sample size was small [70••].

Gastrointestinal (Gi) Tract Microbiome in Prostate Cancer Patients

Studies investigating the role of the gut microbiome in prostate cancer patients are also small in number. The major component of gram-negative bacteria, lipopolysaccharide

(LPS), is able to promote the upregulation of NF- κ B and inflammatory cytokines release, which could increase the risk of prostate cancer metastasis in a rat animal model [71]. The increased signaling of NF- κ B is also discovered in prostate cancer [72]. A study attempted to evaluate the fecal microbiome by performing rectal swabs in both prostate cancer patients and healthy subjects, in which overlapping presence of bacteria was found, but *Bacteroides* and *Streptococcal* bacteria were mostly found in prostate cancer patients [73]. Another study also discovered a higher proportion of *Bacteroidetes* among prostate cancer patients [74••]. A different result was reported by another study which found no difference in the bacterial results obtained via rectal swab between prostate cancer and BPH patients [70••]. One study attempted to analyze the association between the oral microbiome and prostatic fluid. In patients with mild chronic periodontitis, most of them also had one or more similar bacteria in their prostatic fluid. However, the small sample size and lack of a control group made the results less impactful [26].

Regular consumption of dairy products, red meat, and high fat is believed to be associated with prostate cancer occurrence [75]. Several carcinogenic metabolites are produced by gut microbes, including polyamine, ammonia, and N-nitroso components [76]. The excessive production of polyamine could cause a toxic effect via polyamine catabolism resulting in many free radicals [77]. Several studies reported the role of spermine polyamine in urine as a biomarker for prostate cancer [78]. However, it is difficult to determine whether the spermine was produced by bacteria or the patient's own metabolism. Several types of antibiotics are suggested to cause dysbiosis, which can increase the risk of pathogenic bacteria translocation and chronic inflammation of the prostate [79]. The risk of prostate cancer seems to increase with the use of quinolones, tetracyclines, sulfonamides, and penicillin [80]. Several chemotherapeutic drugs, such as cyclophosphamide may also cause shortening of the gut intestinal wall villi, causing microbes to cross and enter the systemic circulation [81]. Several gram-positive bacteria such as *Enterococcus hirae*, *Lactobacillus murinus*, and *Lactobacillus johnsonii*, were also discovered to be necessary for mediating the cyclophosphamide stimulation of response from type 17 T helper (TH17) cells and type 1 T helper (Th1) cells [82].

Clinical Application

The microbes residing in the GI tract are involved in drug metabolism and pharmacokinetics [83, 84]. The alterations of the gut microbiota composition in both BPH and prostate cancer patients receiving a specific pharmacological treatment have been reported in recent years [85]. Several studies noticed the effects of androgen deprivation therapy

(ADT) on the gut microbes in an animal model [86]. Sfanos et al. discovered a higher diversity of microbes based on the rectal swab of BPH patients compared to prostate cancer patients undergoing ADT [87••]. There is an increase of *Akkermansia muciniphila* and *Ruminococcaceae* among patients consuming abiraterone acetate (AA) and enzalutamide, as opposed to patients taking gonadotropin-releasing hormone agonist and antagonist. Several species of bacteria are capable of steroid and hormone biosynthesis, which could influence treatment response. However, the clinical significance of this finding is unclear [87••]. Another study attempted to further elaborate on this finding. They reported that the administration of sole ADT or ADT and AA might reduce *Corynebacterium* species relying on androgens while increasing the population of *Akkermansia muciniphila*. These findings suggested that AA could be used as a fuel for the bacteria in prostate cancer patients. In the GI specimens of these patients, vitamin K2 biosynthesis-related pathways were increased [88]. As an anti-cancer agent, capable of inhibiting tumor growth in prostate cancer animal models, vitamin K2 role is important. The efficacy of AA for treating castration-resistant prostate cancer (mCRPC) may be supported by the increase of vitamin K2 synthesis by the bacteria [89]. Regarding immunotherapy, the presence of *Akkermansia muciniphila* in the gastrointestinal tract is suggested to influence response to anti-PD-1 immunotherapy. However, since the use of immunotherapy in prostate cancer is still limited, studies evaluating immunotherapy and microbiome in prostate cancer patients are less relevant [90•]. The therapy has not been effective for prostate cancer, which contains scarce tumor infiltrating lymphocytes. However, a recent animal model study has demonstrated the use of a uropathogenic *Escherichia coli* isolated from the prostatic secretions of chronic prostatitis patients, to induce infiltration by anti-tumor immune cell types, increase immunogenicity of the tumor, and decrease the immunosuppressive cells in the tumor microenvironment. The processes resulted in a strong clinical benefit in combination with the programmed cell death protein 1 (PD-1) blockade [91].

Future Studies

Before planning or conducting future studies, most current studies agreed that it is essential to standardize the procedures and techniques for sample collection. With a standard procedure, the results from various studies would be less biased and comparable to make a definite conclusion [92]. The variety of findings in currently available studies made it difficult to determine whether the discovered microbes do have a role in prostate carcinogenesis or are merely coincidental. However, we can't deny that the abundant findings of studies indicate that the potential discovery of a prostate

cancer microbiome exists and remains to be seen. Additionally, a study evaluating the carcinogenic role of bacterial products instead of the presence of the bacteria themselves should be performed in the future as the microbiome of the prostate becomes fully understood.

Conclusions

The role of either prostate, urinary, or GI microbiome is still being investigated with no definite conclusion as of the conduction of this review as the currently available studies present various conflicting results with a huge potential for bias. Standardized methods of sampling and analysis with proper prevention measurements for risk of contamination should be determined. Nevertheless, the currently available studies have shown that prostate cancer specimens contain bacterial DNA, not found in healthy prostate tissue. Even though the link between the specific microbiome and prostate cancer has not been established, findings suggest that chronic inflammation and immune system modulation associated with the microbiome are the underlying mechanisms increasing the risk of prostate cancer development.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Not applicable.

Declarations

Conflict of Interest Yudhistira Pradnyan Klopung and Lukman Hakim declare that they have no conflicts of interest.

Informed Consent Not applicable.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. *PLoS Biol.* 2016;14:e1002533.
2. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. *Nat Rev Genet.* 2012;13:260–70.
3. Malard F, Dore J, Gaugler B, et al. Introduction to host microbiome symbiosis in health and disease. *Mucosal Immunol.* 2021;14:547–54.
4. Wheeler KM, Liss MA. The microbiome and prostate cancer risk. *Curr Urol Rep.* 2019;20:1–9.
5. Benson AK, Kelly SA, Legge R, et al. Individuality in gut microbiota composition is a complex polygenic trait shaped

- by multiple environmental and host genetic factors. *Proc Natl Acad Sci.* 2010;107:18933–8.
6. Chen C, Huang X, Fang S, et al. Contribution of host genetics to the variation of microbial composition of cecum lumen and feces in pigs. *Front Microbiol.* 2018;9:2626.
 7. Thursby E, Juge N. Introduction to the human gut microbiota. *Biochem J.* 2017;474:1823–36.
 8. Porter CM, Shrestha E, Peiffer LB, et al. The microbiome in prostate inflammation and prostate cancer. *Prostate Cancer Prostatic Dis.* 2018;21:345–54.
 9. Olejniczak-Staruch I, Ciążyńska M, Sobolewska-Sztychny D, et al. Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis. *Int J Mol Sci.* 2021;22:3998.
 10. Hedin CRH, Sonkoly E, Eberhardson M, Ståhle M. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. *J Intern Med.* 2021;290(2):257–78.
 11. Benahmed AG, Gasmi A, Doşa A, et al. Association between the gut and oral microbiome with obesity. *Anaerobe.* 2021;70:102248.
 12. Young C, Wood HM, Seshadri RA, et al. The colorectal cancer-associated faecal microbiome of developing countries resembles that of developed countries. *Genome Med.* 2021;13:1–13.
 13. Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. *Am J Clin Exp Urol.* 2013;1:3.
 14. Peisch SF, Van Blarigan EL, Chan JM, et al. Prostate cancer progression and mortality: a review of diet and lifestyle factors. *World J Urol.* 2017;35:867–74.
 15. Klein CA. Cancer progression and the invisible phase of metastatic colonization. *Nat Rev Cancer.* 2020;20:681–94.
 16. Hui L, Chen Y. Tumor microenvironment: Sanctuary of the devil. *Cancer Lett.* 2015;368:7–13.
 17. Wu T, Dai Y. Tumor microenvironment and therapeutic response. *Cancer Lett.* 2017;387:61–8.
 18. Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. *CA Cancer J Clin.* 2017;67:326–44.
 19. Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. *Gut.* 2018;67:226–36.
 20. Massari F, Mollica V, Di Nunno V, et al. The human microbiota and prostate cancer: friend or foe? *Cancers (Basel).* 2019;11:459.
 21. Ocariz-Diez M, Cruellas M, Gascón M, et al. Microbiota and lung cancer. Opportunities and challenges for improving immunotherapy efficacy. *Front Oncol.* 2020;10:1945.
 - 22.● Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71:209–249. **Prostate cancer is the one of the most common cancers among men in the world.**
 23. Hayward SW, Cunha GR. The prostate: development and physiology. *Radiol Clin North Am.* 2000;38:1–14.
 24. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. *Nat Rev Cancer.* 2007;7(4):256–69.
 25. Tomas D, Krušlin B, Rogatsch H, et al. Different types of atrophy in the prostate with and without adenocarcinoma. *Eur Urol.* 2007;51:98–104.
 26. Estemalik J, Demko C, Bissada NF, et al. Simultaneous detection of oral pathogens in subgingival plaque and prostatic fluid of men with periodontal and prostatic diseases. *J Periodontol.* 2017;88:823–9.
 27. Kadosh E, Snir-Alkalay I, Venkatachalam A, et al. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. *Nature.* 2020;586:133–8.
 28. OhadianMoghadam S, Momeni SA. Human microbiome and prostate cancer development: current insights into the prevention and treatment. *Front Med.* 2021;15:11–32.
 29. Huycke MM, Gaskins HR. Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. *Exp Biol Med.* 2004;229:586–97.
 30. Carbonero F, Benefiel AC, Alizadeh-Ghamsari AH, et al. Microbial pathways in colonic sulfur metabolism and links with health and disease. *Front Physiol.* 2012;3:448.
 31. Kelly SP, Anderson WF, Rosenberg PS, et al. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. *Eur Urol Focus.* 2018;4:121–7.
 32. Conteduca V, Crabb SJ, Jones RJ, et al. Persistent neutrophil to lymphocyte ratio > 3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. *PLoS One.* 2016;11:e0158952.
 33. Che B, Zhang W, Xu S, Yin J, He J, Huang T, Li W, Yu Y, Tang K. Prostate microbiota and prostate cancer: a new trend in treatment. *Front Oncol.* 2021;11.
 34. Abidi SH, Bilwani F, Ghias K, et al. Viral etiology of prostate cancer: genetic alterations and immune response. A literature review. *Int J Surg.* 2018;52:136–40.
 35. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1.2016. *J Natl Compr Cancer Netw.* 2016;14:19–30.
 36. Zarei A, Javid H, Sanjarian S, et al. Metagenomics studies for the diagnosis and treatment of prostate cancer. *Prostate.* 2022;82:289–97.
 37. Chilakapati SR, Ricciuti J, Zsiros E. Microbiome and cancer immunotherapy. *Curr Opin Biotechnol.* 2020;65:114–7.
 - 38.●● Golombos DM, Ayangbesan A, O'Malley P, et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. *Urology.* 2018;111:122–128. **The study reported the enrichment of several bacteria in the feces of prostate cancer and BPH patients.**
 - 39.●● Shrestha E, White JR, Yu S-H, et al. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. *J Urol.* 2018;199:161–171. **This is the most comprehensive study to date regarding the male urinary microbiome and its association with prostate cancer. These results suggest the presence of pro-inflammatory bacteria and pathogens in the urinary tract of prostate cancer patients.**
 - 40.●● Hochreiter WW, Duncan JL, Schaeffer AJ. Evaluation of the bacterial flora of the prostate using a 16S rRNA gene based polymerase chain reaction. *J Urol.* 2000;163:127–130. **This is one of the first studies evaluating the bacterial flora of the prostate using a 16S rRNA gene-based polymerase chain reaction.**
 - 41.●● Cavarretta I, Ferrarese R, Cazzaniga W, et al. The microbiome of the prostate tumor microenvironment. *Eur Urol.* 2017;72:625–631. **They discovered significant differences in specific microbial populations among tumor or peri-tumor and non-tumor prostate specimens.**
 42. Shinohara DB, Vaghasia AM, Yu S, et al. A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of *Propionibacterium acnes*. *Prostate.* 2013;73:1007–15.
 - 43.●● Glassing A, Dowd SE, Galandiuk S, et al. Inherent bacterial DNA contamination of extraction and sequencing reagents may affect interpretation of microbiota in low bacterial biomass samples. *Gut Pathog.* 2016;8:1–12. **The study suggested the possibility of bacterial DNA contamination, which may affect the interpretation of microbiota in low bacterial biomass samples.**

44. Ghosh SK, Feng Z, Fujioka H, et al. Conceptual perspectives: Bacterial antimicrobial peptide induction as a novel strategy for symbiosis with the human host. *Front Microbiol.* 2018;9:302.
45. Eisenhofer R, Minich JJ, Marotz C, et al. Contamination in low microbial biomass microbiome studies: issues and recommendations. *Trends Microbiol.* 2019;27:105–17.
46. ●● Feng Y, Ramnarine VR, Bell R, et al. Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. *BMC Genomics.* 2019;20:1–8. **This is the first human prostate microbiome study with an integrated metagenomics and metatranscriptomics approach. They discovered a non-sterile microenvironment in the prostate of prostate cancer patients, but they did not find a link between the microbiome and cancer local progression. There is however evidence that pseudomonas infection may impede metastasis.**
47. ●● Banerjee S, Alwine JC, Wei Z, et al. Microbiome signatures in prostate cancer. *Carcinogenesis* 2019;40:749–764. **Viral and helicobacter involvements are believed to affect the expression of several cellular genes associated with oncogenic processes.**
48. ● Al-Marhoon MS, Ouhtit A, Al-Abri AO, et al. Molecular evidence of *Helicobacter pylori* infection in prostate tumors. *Curr Urol.* 2014;8:138–143. **This is the first study that provided molecular evidence of *H. pylori* DNA presence in the prostatic tissue of BPH and prostate cancer patients.**
49. Markowski MC, Boorjian SA, Burton JP, et al. The microbiome and genitourinary cancer: a collaborative review. *Eur Urol.* 2019;75:637–46.
50. Namiki K, Goodison S, Porvasnik S, et al. Persistent exposure to *Mycoplasma* induces malignant transformation of human prostate cells. *PLoS One.* 2009;4:e6872.
51. Miyake M, Ohnishi K, Hori S, et al. *Mycoplasma genitalium* infection and chronic inflammation in human prostate cancer: detection using prostatectomy and needle biopsy specimens. *Cells.* 2019;8:212.
52. Huang W-Y, Hayes R, Pfeiffer R, et al. Sexually transmissible infections and prostate cancer risk. *Cancer Epidemiol Prev Biomarkers.* 2008;17:2374–81.
53. ●● Yu H, Meng H, Zhou F, et al. Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia. *Arch Med Sci AMS.* 2015;11:385. **There are changes in the microbial population in EPS, urine, and seminal fluid between BPH and prostate cancer, suggesting a potential role for the bacteria in two different conditions.**
54. Samanta M, Harkins L, Klemm K, et al. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. *J Urol.* 2003;170:998–1002.
55. Fioriti D, Videtta M, Mischitelli M, et al. The human polyomavirus BK: Potential role in cancer. *J Cell Physiol.* 2005;204:402–6.
56. Ahn J, Barber GN. STING signaling and host defense against microbial infection. *Exp Mol Med.* 2019;51:1–10.
57. Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, et al. Identification of viral infections in the prostate and evaluation of their association with cancer. *BMC Cancer.* 2010;10:1–7.
58. Cortes GA, Flores JL. Physiology, Urination. *StatPearls [Internet].* 2020.
59. Aragon IM, Herrera-Imbroda B, Queipo-Ortuño MI, et al. The urinary tract microbiome in health and disease. *Eur Urol Focus.* 2018;4:128–38.
60. Neugent ML, Hulyalkar NV, Nguyen VH, et al. Advances in understanding the human urinary microbiome and its potential role in urinary tract infection. *MBio.* 2020;11:e00218-20.
61. Scott RP, Quaggin SE. The cell biology of renal filtration. *J Cell Biol.* 2015;209:199–210.
62. Vervaeck BA, D’Haese PC, Verhulst A. Environmental toxin-induced acute kidney injury. *Clin Kidney J.* 2017;10:747–58.
63. Safwat AS, Hasanain A, Shahat A, et al. Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: A randomized, comparative study. *World J Urol.* 2019;37:1347–52.
64. Sfanos KS, Yegnasubramanian S, Nelson WG, et al. The inflammatory microenvironment and microbiome in prostate cancer development. *Nat Rev Urol.* 2018;15:11–24.
65. Shoskes DA, Altemus J, Polackwich AS, et al. The urinary microbiome differs significantly between patients with chronic prostatitis/chronic pelvic pain syndrome and controls as well as between patients with different clinical phenotypes. *Urology.* 2016;92:26–32.
66. Bajic P, Dornbier RA, Doshi CP, et al. Implications of the genitourinary microbiota in prostatic disease. *Curr Urol Rep.* 2019;20:1–10.
67. Javier-DesLoges J, McKay RR, Swafford AD, Sepich-Poore GD, Knight R, Parsons JK. The microbiome and prostate cancer. *Prostate Cancer Prostatic Dis.* 2021;1–6.
68. Matsushita M, Fujita K, Motooka D, et al. The gut microbiota associated with high-Gleason prostate cancer. *Cancer Sci.* 2021;112:3125.
69. Fan X, Jin Y, Chen G, et al. Gut microbiota dysbiosis drives the development of colorectal cancer. *Digestion.* 2021;102:508–15.
70. ●● Alanee S, El-Zawahry A, Dynda D, et al. A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis. *Prostate.* 2019;79:81–87. **The microbiota of urine in patients with prostate cancer tends to cluster separately without the disease, however further studies are required to investigate the role of the urinary microbiome as a biomarker.**
71. Jain S, Dash P, Minz AP, et al. Lipopolysaccharide (LPS) enhances prostate cancer metastasis potentially through NF-κB activation and recurrent dexamethasone administration fails to suppress it in vivo. *Prostate.* 2019;79:168–82.
72. Lessard L, Begin LR, Gleave ME, et al. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. *Br J Cancer.* 2005;93:1019–23.
73. Katz R, Ahmed MA, Safadi A, et al. Characterization of fecal microbiome in biopsy positive prostate cancer patients. *BJUI Compass.* 2022;3:55–61.
74. ●● Liss MA, White JR, Goros M, et al. Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. *Eur Urol.* 2018;74:575–582. **Microbiome may have slight influences on prostate cancer, but they are likely patient-specific, thus requiring a further paired analysis and precise manipulation.**
75. Lan T, Park Y, Colditz GA, et al. Adolescent dairy product and calcium intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study. *Cancer Causes Control.* 2020;31:891–904.
76. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. *Nat Rev Microbiol.* 2014;12:661–72.
77. Casero RA, Stewart TM, Pegg AE. Polyamine metabolism and cancer: treatments, challenges and opportunities. *Nat Rev Cancer.* 2018;18:681–95.
78. Tsoi T-H, Chan C-F, Chan W-L, et al. Urinary polyamines: a pilot study on their roles as prostate cancer detection biomarkers. *PLoS One.* 2016;11:e0162217.
79. Arora HC, Eng C, Shoskes DA. Gut microbiome and chronic prostatitis/chronic pelvic pain syndrome. *Ann Transl Med.* 2017;5(2).

80. Petrelli F, Ghidini M, Ghidini A, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies. *Cancers (Basel)*. 2019;11:1174.
81. Gori S, Inno A, Belluomini L, et al. Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. *Crit Rev Oncol Hematol*. 2019;143:139–47.
82. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. *Science (80-)*. 2013;342:971–976.
83. Spanogiannopoulos P, Bess EN, Carmody RN, et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. *Nat Rev Microbiol*. 2016;14:273–87.
84. Vázquez-Baeza Y, Callewaert C, Debelius J, et al. Impacts of the human gut microbiome on therapeutics. *Annu Rev Pharmacol Toxicol*. 2018;58:253–70.
85. Borgo F, Macandog AD, Diviccaro S, et al. Alterations of gut microbiota composition in post-finasteride patients: a pilot study. *J Endocrinol Invest*. 2021;44:1263–73.
86. Harada N, Hanaoka R, Hanada K, et al. Hypogonadism alters cecal and fecal microbiota in male mice. *Gut Microbes*. 2016;7:533–9.
87. ● Sfanos KS, Markowski MC, Peiffer LB, et al. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. *Prostate Cancer Prostatic Dis*. 2018;21:539–48. **The study speculated that oral hormonal therapies for prostate cancer may influence GI microbiota and clinical response. Thus antitumor effects of immunotherapy may also be affected. However, further studies are required.**
88. Daisley BA, Chanyi RM, Abdur-Rashid K, et al. Abiraterone acetate preferentially enriches for the gut commensal *Akkermansia muciniphila* in castrate-resistant prostate cancer patients. *Nat Commun*. 2020;11:1–11.
89. Samykutty A, Shetty AV, Dakshinamoorthy G, Kalyanasundaram R, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A, Gnanasekar M. Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. *Evidence-Based Complement Altern Med*. 2013;2013.
90. ● Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. *Science (80-)*. 2018;359:91–97. **Primary resistance of immune checkpoint inhibitors (ICIs) may be affected by abnormal gut microbiome composition, which may be influenced by antibiotics.**
91. Anker JF, Naseem AF, Mok H, et al. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. *Nat Commun*. 2018;9:1–14.
92. Karstens L, Asquith M, Caruso V, et al. Community profiling of the urinary microbiota: considerations for low-biomass samples. *Nat Rev Urol*. 2018;15:735–49.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.